[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE120199A1 - HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE - Google Patents

HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE

Info

Publication number
PE120199A1
PE120199A1 PE1998000949A PE00094998A PE120199A1 PE 120199 A1 PE120199 A1 PE 120199A1 PE 1998000949 A PE1998000949 A PE 1998000949A PE 00094998 A PE00094998 A PE 00094998A PE 120199 A1 PE120199 A1 PE 120199A1
Authority
PE
Peru
Prior art keywords
het
aryl
compound
members
refers
Prior art date
Application number
PE1998000949A
Other languages
Spanish (es)
Inventor
Karen Elizabeth Lackey
Michael Robert Peel
Mui Cheung
Kimberly Caroline Glennon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE120199A1 publication Critical patent/PE120199A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO PIRROLOPIRIDINONA DE FORMULA I; R1 ES HET, ARILO, BIARILO OPCIONALMENTE SUSTITUIDO POR R5, COR5, COOR5 Y OR5; R2 ES H, HET, HET FUSIONADO, ARILO, CN, CONR5R7, ENTRE OTROS; R3 ES H, HET, ARILO, NO2, OR5, ENTRE OTROS; R4 ES H, HET, ARILO, CN, NO2, ENTRE OTROS; R5 ES H, HET, ARILO, HALOGENO, ENTRE OTROS; R6 ES H, UN GRUPO ALIFATICO C1-C12, HET O ARILO; R7 ES H o R5; HET ES UN ANILLO DE 5-10 MIEMBROS COMO ACRIDINA, BENCIMIDAZOL, BENZOFURANO, ENTRE OTROS; HET FUSIONADO, CUANDO R2 Y R3 O R3 Y R4 FORMAN JUNTOS UN ARILO, HETEROARILO, DE 5-10 MIEMBROS, ENTRE OTROS. UN COMPUESTO PREFERIDO ES 3-(3,5-DIBROMO-4-HIDROXI-BENCILIDENO)-5-FENIL-1,3-DIHIDRO-PIRROLO[2,3-n]PIRIDIN-2-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I INHIBE A LA CINASA ACTIVADA CON MITOGENOS; POR LO QUE PUEDE SER UTIL PARA INHIBIR EL CRECIMIENTO DEL TUMOR, PREVENIR EL RECHAZO DE TRASPLANTE DE ORGANOS, CURAR UNA HERIDA CRONICA O TRATAR LA RESTENOSIS, ARTRITIS REUMATOIDEIT REFERS TO A FORMULA I PIRROLOPYRIDINONE COMPOUND; R1 IS HET, ARYL, BIARILE OPTIONALLY REPLACED BY R5, COR5, COOR5 AND OR5; R2 IS H, HET, FUSED HET, ARYL, CN, CONR5R7, AMONG OTHERS; R3 IS H, HET, ARYL, NO2, OR5, AMONG OTHERS; R4 IS H, HET, ARYL, CN, NO2, AMONG OTHERS; R5 IS H, HET, ARYL, HALOGEN, AMONG OTHERS; R6 IS H, A C1-C12 ALIPHATIC GROUP, HET OR ARYL; R7 IS H or R5; HET IS A RING OF 5-10 MEMBERS LIKE ACRIDINE, BENZIMIDAZOLE, BENZOFURANO, AMONG OTHERS; FUSED HET, WHEN R2 AND R3 OR R3 AND R4 TOGETHER TOGETHER A RING, HETEROARILO, OF 5-10 MEMBERS, AMONG OTHERS. A PREFERRED COMPOUND IS 3- (3,5-DIBROMO-4-HIDROXI-BENCILIDENO) -5-FENIL-1,3-DIHIDRO-PIRROLO [2,3-n] PIRIDIN-2-ONA, AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. COMPOUND I INHIBITS MITOGEN ACTIVATED KINASE; SO IT CAN BE USEFUL TO INHIBIT THE GROWTH OF TUMOR, PREVENT ORGAN TRANSPLANT REJECTION, HEAL A CHRONIC WOUND OR TREAT RESTENOSIS, RHEUMATOID ARTHRITIS

PE1998000949A 1997-10-10 1998-10-07 HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE PE120199A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721437.3A GB9721437D0 (en) 1997-10-10 1997-10-10 Heteroaromatic compounds and their use in medicine

Publications (1)

Publication Number Publication Date
PE120199A1 true PE120199A1 (en) 1999-12-15

Family

ID=10820303

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000949A PE120199A1 (en) 1997-10-10 1998-10-07 HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE

Country Status (7)

Country Link
AR (1) AR017311A1 (en)
AU (1) AU1151099A (en)
GB (1) GB9721437D0 (en)
MA (1) MA26550A1 (en)
PE (1) PE120199A1 (en)
WO (1) WO1999021859A1 (en)
ZA (1) ZA989249B (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1005470B1 (en) 1997-08-22 2007-08-01 AstraZeneca AB Oxindolylquinazoline derivatives as angiogenesis inhibitors
ATE482946T1 (en) 1999-02-10 2010-10-15 Astrazeneca Ab QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATE PRODUCTS THEREFOR
US7083791B2 (en) 1999-03-25 2006-08-01 Genesis Research & Development Corporation Limited Methods for enhancing immune responses by fibroblast growth factor receptor 5 polypeptides
US20030143676A1 (en) * 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
EP1088821A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
SE9904177D0 (en) * 1999-11-18 1999-11-18 Astra Ab Novel compounds
CA2395520A1 (en) 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
US6323029B1 (en) 2000-01-19 2001-11-27 Isis Pharmaceuticals, Inc. Antisense modulation of glycogen synthase kinase 3 beta expression
US6316259B1 (en) 2000-01-21 2001-11-13 Isis Pharmaceuticals, Inc. Antisense inhibition of glycogen synthase kinase 3 alpha expression
AU2001236720A1 (en) * 2000-02-05 2001-08-14 Bemis, Guy Compositions useful as inhibitors of erk
FR2804959B1 (en) * 2000-02-15 2006-04-28 Centre Nat Rech Scient USE OF PAULLON DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS
JP2003525296A (en) * 2000-02-28 2003-08-26 スージェン・インコーポレーテッド 3- (pyrrolyllactone) -2-indolinone compounds as kinase inhibitors
EP1313726A1 (en) 2000-08-09 2003-05-28 AstraZeneca AB Quinoline derivatives having vegf inhibiting activity
CA2415022A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Cinnoline compounds
EP1347972A1 (en) * 2000-12-19 2003-10-01 Smithkline Beecham Plc Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors
DE60122939T2 (en) 2000-12-21 2007-01-11 Nitromed, Inc., Bedford SUBSTITUTED ARYL COMPOUNDS AS NEW, CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS, AND USE PROCESSES
SE0101230L (en) * 2001-04-06 2002-10-07 Innoventus Project Ab New use of a tyrosine kinase inhibitor
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
AU2002259071A1 (en) * 2001-04-30 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes
ATE330608T1 (en) * 2001-06-29 2006-07-15 Ab Science THE USE OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
DE60227709D1 (en) * 2001-06-29 2008-08-28 Ab Science THE USE OF C-CRITERIA FOR THE TREATMENT OF AUTOIMMUNE DISEASES
JP2005500041A (en) 2001-06-29 2005-01-06 アブ サイエンス Potent, selective and non-toxic C-KIT inhibitor
JP2004530730A (en) * 2001-06-29 2004-10-07 アブ サイエンス Use of a potent, selective and non-toxic c-kit inhibitor for treating tumor angiogenesis
DK1401413T3 (en) * 2001-06-29 2007-03-26 Ab Science Use of tyrosine kinase inhibitors for the treatment of allergic diseases
WO2003004007A2 (en) 2001-06-29 2003-01-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
ES2275021T3 (en) * 2001-09-27 2007-06-01 Smithkline Beecham Corporation DERIVATIVES OF AZOXOINDOL AS INHIBITORS OF TRK PROTEIN KINASE FOR THE TREATMENT OF CANCER AND CHRONIC PAIN.
NZ534171A (en) 2002-02-01 2007-06-29 Astrazeneca Ab Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability
US7534800B2 (en) 2002-03-28 2009-05-19 Eisai R & D Development Co., Ltd. 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders
IL164082A0 (en) 2002-03-28 2005-12-18 Eisai Co Ltd Azaindole derivatives and pharmaceutical compositions containing the same
EP1501511A4 (en) * 2002-05-06 2006-06-07 Univ Washington Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
EP1599475A2 (en) 2003-03-06 2005-11-30 Eisai Co., Ltd. Jnk inhibitors
EP1628975A2 (en) 2003-05-16 2006-03-01 Eisai Co., Ltd. Jnk inhibitors
AR045037A1 (en) 2003-07-10 2005-10-12 Aventis Pharma Sa TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE.
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0402137D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
KR101216372B1 (en) * 2004-03-30 2013-01-04 버텍스 파마슈티칼스 인코포레이티드 Azaindoles useful as inhibitors of JAK and other protein kinases
NZ550448A (en) * 2004-05-14 2010-11-26 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005113561A1 (en) * 2004-05-20 2005-12-01 Sugen, Inc. Cyclicsulfonate pyrrole indolinones as kinase inhibitors
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
JP2009503001A (en) * 2005-08-01 2009-01-29 エフ.ホフマン−ラ ロシュ アーゲー Heterocyclic benzylamino derivatives, their production and use as pharmaceuticals
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (en) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Regulation of neurogenesis by PDE inhibition
JP5324785B2 (en) 2005-10-28 2013-10-23 武田薬品工業株式会社 Heterocyclic amide compounds and uses thereof
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007084557A2 (en) 2006-01-17 2007-07-26 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of janus kinases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007245495A1 (en) 2006-04-26 2007-11-08 Astex Therapeutics Limited Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
NZ577798A (en) 2006-12-21 2012-04-27 Vertex Pharma 5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
BRPI0821227A2 (en) 2007-12-19 2015-06-16 Cancer Rec Tech Ltd Compound, pharmaceutical composition, method for preparing same, use of a compound, method for treating a disease or disorder, for inhibiting raf function and for inhibiting cell proliferation, inhibiting cell cycle progression, promoting apoptosis, or a combination of one or more more of them
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2379561B1 (en) 2008-11-25 2015-11-04 University Of Rochester Mlk inhibitors and methods of use
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
DK2442809T3 (en) 2009-06-17 2016-12-19 Vertex Pharma Inhibitors of the replication of influenza virus
PL2531502T3 (en) 2010-02-01 2014-08-29 Cancer Research Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
CN103153994B (en) 2010-05-24 2016-02-10 罗切斯特大学 Bicyclic heteroaryl kinase inhibitor and using method
KR20140014110A (en) 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of influenza viruses replication
CN102115469A (en) * 2011-03-21 2011-07-06 浙江大学 Preparation method for indoline-2-one derivative and application of same
US9493452B2 (en) * 2011-03-24 2016-11-15 Southern Methodist University Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors
US8669363B2 (en) 2011-03-24 2014-03-11 Southern Methodist University Quinoxaline compounds and derivatives
CN103702998A (en) 2011-07-05 2014-04-02 沃泰克斯药物股份有限公司 Processes and intermediates for producing azaindoles
UA118010C2 (en) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
PT2807160T (en) * 2012-01-26 2019-10-28 Angion Biomedica Corp Antifibrotic compounds and uses thereof
WO2013142831A1 (en) 2012-03-23 2013-09-26 Southern Methodist University Methods of making and using thioxothiazolidine and rhodanine derivatives as hiv-1 and jsp-1 inhibitors
CN104884059B (en) 2012-11-30 2018-08-10 罗切斯特大学 Mixing pedigree kinase inhibitor for HIV/AIDS treatments
CN108276278B (en) 2013-11-13 2021-04-20 沃泰克斯药物股份有限公司 Method for preparing influenza virus replication inhibitor
PT3068776T (en) 2013-11-13 2019-08-26 Vertex Pharma Inhibitors of influenza viruses replication
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
CN104447733B (en) * 2015-01-05 2016-08-17 中国药科大学 1-benzyl-2-pyrrolinone-4-amides compound and preparation method and application
CN104876928B (en) * 2015-05-07 2016-09-14 浙江司太立制药股份有限公司 7-azaindole quinoline-2-ketone compounds and preparation method thereof
MA42422A (en) 2015-05-13 2018-05-23 Vertex Pharma INHIBITORS OF INFLUENZA VIRUS REPLICATION
JP6704416B2 (en) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Methods for preparing inhibitors of influenza virus replication
JP6661766B2 (en) * 2015-11-12 2020-03-11 エルジー・ケム・リミテッド Pharmaceutical composition containing a 7-azaindoline-2-one derivative or a pharmaceutically acceptable salt thereof as an active ingredient
PT3466934T (en) 2016-05-31 2024-04-30 Taiho Pharmaceutical Co Ltd Sulfonamide compound or salt thereof
US10889555B2 (en) 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
CN106432228A (en) * 2016-09-06 2017-02-22 浙江司太立制药股份有限公司 4-oximido-1-piperidyl fragment containing 7-azaindolin-2-one compound and preparation method therefor
CN106397436A (en) * 2016-09-06 2017-02-15 浙江司太立制药股份有限公司 5-bromo-7-azaindoline-2-one compounds and preparation method thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423997D0 (en) * 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation

Also Published As

Publication number Publication date
AR017311A1 (en) 2001-09-05
WO1999021859A1 (en) 1999-05-06
ZA989249B (en) 2000-04-10
MA26550A1 (en) 2004-12-20
GB9721437D0 (en) 1997-12-10
AU1151099A (en) 1999-05-17

Similar Documents

Publication Publication Date Title
PE120199A1 (en) HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE
PE112699A1 (en) DERIVATIVES OF BENCILIDENO-1,3-DIHIDRO-INDOL-2-ONA THAT HAVE ANTI-CANCER ACTIVITY
CO5200785A1 (en) THERAPEUTIC USE OF QUINAZOLINE
ID28362A (en) 4-AMINOPIROLOPIRIMIDINA AS A CINNAMER INVOLVEMENT
ATE116317T1 (en) QUINUCLIDINE DERIVATIVES.
ATE264846T1 (en) SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR TREATING RETROVIRAL INFECTIONS
BG105346A (en) Pyrolopyrimidines as protein kinase inhibitors
EA199900693A1 (en) Atropisomers of 3-aryl-4 (3H) -CHINAZOLINONES AND THEIR USE AS ANTAGONISTS OF AMPA RECEPTORS
PE20020485A1 (en) QUINOLINE AND QUINAZOLINE DERIVATIVES AS NEUROPEPTIDE ANTAGONISTS AND
ES2031513T3 (en) QUINAZOLINDIONAS AND PIRIDOPIRIMIDINADIONAS.
BR9814361A (en) Inhibition of raf kinase using heterocyclic urea substituted by heteroaryl aryl
DE60112268D1 (en) USE OF QUINAZOLIN DERIVATIVES AS INHIBITORS OF ANGIOGENESIS
AR049239A1 (en) INHIBITING HETEROCICLIC COMPOUNDS OF KINASA PROTEIN (ERK-2) AND INHIBITION METHOD
DE69325662D1 (en) DOPAMINE RECEPTOR SUBTYPE LIGANDS
ATE186301T1 (en) 4H-PYRIDO-(1,2-A)PYRIMIDINE-4-ONE SUBSTITUTED AT POSITIONS 2 AND 9
AR054364A1 (en) COMPOUNDS WITH STRUCTURE OF 1- (IMIDAZOLIN -2-IL-) AMINO -1,2-DIFENYLETHANE TO COMBAT ANIMAL PESTS
ATE324890T1 (en) COMPOSITION CONTAINING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A DIURETIC AND THE USE THEREOF FOR THE TREATMENT OF HYPERTENSION
ES2111930T3 (en) AMP ACID ANTAGONISTS AND TREATMENT PROCEDURES WITH THE HELP OF THESE.
DE69409796D1 (en) NEW USE TO HETEROCYCLIC COMPOUNDS AND THEIR COMPOSITIONS
ATE197401T1 (en) QUINAZOLINONE DRUGS AND THEIR USE
FI95565B (en) Process for the preparation of therapeutically useful amidines and guanidines
DE69127072D1 (en) SUBSTITUTED UREAS, PRODUCTION AND USE
ATE519762T1 (en) BENZAZEPINE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR AND THEIR USE
DK0430551T3 (en) Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
DK225187D0 (en) PYRIDYLYCYLOPROPANCER CARBOXAMIDES WITH FUNGICIDIC EFFECT

Legal Events

Date Code Title Description
FA Abandonment or withdrawal